INCLIVA Biomedical Research Institute
INCLIVA is a
top 10 biomedical research institute in Spain. It is organized around four
priority areas of research: cardiovascular, oncology, metabolism and organic
damage and reproductive medicine. INCLIVA is included in the framework of
centres of scientific excellence promoted by the Spanish Government, and it has
been accredited by the National Health Institute Carlos III as an Institute of
Research in Health Sciences. INCLIVA is the institution managing the research
in the area of Health produced by the University of Valencia as its natural
third party (School of Medicine),
Igenomix Research Foundation and the
University Clinic Hospital that includes a health department providing
healthcare to the 350.000 inhabitants with a EHR that virtually covers the
whole population of the department.
INCLIVA has participated in FP6, FP7 and H2020 research projects funded by the
European Commission and boasts a thick network of relationships with the major
European scientific institutions and scientific societies that will place to
the benefit of the project.
last 10 years, INCLIVA has been supporting its researchers in their knowledge
management practices (financial planning and programmes for the valorisation of
research results, support in the technology transfer and integration of
information and communication technologies). INCLIVA has produced over 600
international publications with a average impact factor of 5.7 in the last year
and has carried out over 200 granted competitive projects, including European
Framework Programme cooperation major projects. Finally, regarding knowledge
transfer INCLIVA has participated in the generation of 11 patent requests since 2015.
Our research is articulated around 4 priority research pillars led by well-rewarded researchers: oncology, cardiovascular, metabolism and organ damage and reproductive medicine. Aiming at adopting a translational perspective, this 4 pillar are implemented in 7 scientific areas, each of them oriented to a specific disease: overweight and vascular and renal risk; myocardial ischemic damage; rare diseases; neurological impairment; translational oncology; reproductive medicine and aging.
INCLIVA's Innovation Unit is the technology transfer office (TTO) of the Hospital Clínico Universitario of Valencia (HCUV) and INCLIVA Biomedical Research Institute, promoting and managing the innovations conceived within these entities. Other roles of our innovation unit include: scouting of knowledge-based assets inside the organization, patent portfolio management and, especially, management of innovative and proof of concept projects.
The innovation unit is a ITEMAS's partner since 2014, it is officially registered as TTO with the number 258 at the Spanish Sciencie Ministry and it is certified in the standrad UNE166002 for Rinnovation management.
The innovation unit team includes Pedro Fernández Nohales, PhD, RTTP as the manager of the unit, Vanesa Carretero, MSc as technician and Rafael Barajas, MSc, giving support in all the innovative projects in the area of bigdata as INCLIVA's Data Protection Manager.
Concerning ITEMAS membership, INCLIVA's innovation unit is funded by ISCIII (grant no. PT17/005/0017) and Prof. Josep Redón, PhD, MD is the principal investigator and scientific responsible of the unit.
- Personalised prosthesis for jaw and facial bones
- Diagnostic procedure to identify patients with Minimal Hepatic Encephalopathy
- Method for measuring cardiovascular fitness in youth
- Procedure for articular cartilage regeneration
- Novel compounds for the treatment of metabolic syndrome and associated morbilities
- Biomarkers for melanoma prognosis
- NEW TOOLS FOR DIAGNOSIS; PREDICTION AND PREVENTION OF MYOCARDIAL IFARCTION
- CARECV: A software for determining the cardiac extracellular volume
- COMPOUND FOR PREVENTATIVE TREATMENT OF ALZHEIMER DISEASE
- ANGIOPATH: A TOOL TO QUANTIFY AND MORPHOLOGICALLY CHARACTERIZE BLOOD AND LYMPH VESSELS
- METHOD FOR PREDICTING THE PROGNOSIS AND PROBABLE EVOLUTION OF PATIENTS WITH SEPSIS, SEVERE SEPSIS, AND SEPTIC SHOCK
- Epidisease: an INCLIVA spin off
- Seqplexing: an INCLIVA spin off